GPN Vaccines

Canberra, Australia · Founded 2017 · Privately Held (backing)

Developer of vaccines intended to offer protection against pneumococcal bacteria, the world's foremost bacterial pathogen. GPN Vaccines is based in Canberra, Australia and was founded in 2017. Its last reported valuation was $300 million in Jun 2024. It has raised $27.7 million across 1 recorded round; the latest was a $3.5 million seed round in Dec 2025.

Last reported valuation
$300.0M
Oct 2026
Priced at
—
Total raised
$27.7M
Last round
Seed Round
Dec 2025

Who backs GPN Vaccines?

7 investors
InvestorType
Shearwater CapitalOther
Brandon Biocatalyst—
Forepont Capital Partners—
Kern Capital—
Mike Gregg—
South Australian Government—
Southern Angels—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

GPN Vaccines investors

7 investors are on record for GPN Vaccines, including Shearwater Capital, Brandon Biocatalyst, Forepont Capital Partners and Kern Capital. The seed round in Dec 2025 drew 63 investors.

Free account
More of GPN Vaccines with a free account
  • ·Watch GPN Vaccines: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 7 firms already write checks for companies like GPN Vaccines. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View